The FINANCIAL — The Association of German Medical Journalists [Verband Deutscher Medizinjournalisten, VDMJ] presented for the first time the Advances in Renal Cancer Journalists’ Award Europe, which is sponsored by Bayer HealthCare AG and endowed with EUR 7,500, for the first time today.
The award was presented on May 8, 2009 at the EU-KCA Symposium in Berlin.
The award went to journalist Malini Guha for her article “New advances deliver fresh hope in kidney cancer”, which was published in the international journal Scrip on February 13, 2009.
The jury – comprising Professor Peter Mulders, Department of Urology, University Medical Center St. Radboud, Nijmwegen (the Netherlands), Dr. Bernard Escudier, Institut Gustave Roussy, Villejuif (France) and Torsten Hoffmann, President of the VdMJ, Stuttgart (Germany) – this year evaluated submissions from printed media.
In her article, Malini Guha provides a concise and informative review of the current options and prospects of success in the treatment of renal cell carcinoma. The article comes across as both scientifically accurate and clearly comprehensible, aiming to give interested readers the necessary information on the latest research into treatment in this indication in a manner that is comprehensive and yet not overtaxing.
Within the feature article, Malini Guha focuses on progress in the treatment of carcinomas of the kidney in recent years and examines the outlook for other approaches. Her writing adheres to the guiding principle of medical journalism: “do not stir up anxiety and do not raise unreasonable hopes”. The article is a testament to the detailed investigative work conducted by Malini Guha herself at research centers, hospitals and amongst specialist oncologists. This, too, is a mark of good journalistic practice. Furthermore, the journalist’s own personal interest in the subject matter also contributes to the success of this commendable publication.
Malini Guha is Scientific Editor of London-based Scrip World Pharmaceutical News. In the editorial department of this renowned British trade publication, she is responsible for the Research & Development section, which reports principally on clinical trials, product approvals and product safety. Guha’s particular interests lie in oncology. Her journalistic output has included a number of reports on kidney cancer, as she feels that this indication is one of the most exciting in the field of research into cancer drugs.
Malini Guha studied journalism and political sciences in London and at Yale University in New Haven, USA.
Discussion about this post